Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice

European Journal of Clinical Investigation

Volumn 36, Issue 6, 2006, Pages 409-418

  Li, X ^a   Lu, W L ^a   Liang, G W ^a   Ruan, G R ^b   Hong, H Y ^c   Long, C ^c   Zhang, Y T ^a   Liu, Y ^a   Wang, J C ^a   Zhang, X ^a   Zhang, Q ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Amlodipine; Antileukaemia activity; Apoptosis; Caspases; Multidrug resistance; Pharmacokinetics; Stealthy liposomal topotecan

Indexed keywords

AMLODIPINE; CASPASE 3; CASPASE 7; CASPASE 8; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; STEALTHY LIPOSOMAL TOPOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MOUSE STRAIN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; XENOGRAFT;

AMLODIPINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33646704493     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01643.x     Document Type: Article

References (38)

1. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005 68 : 293 8.
2. Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 2005 11 : 5912 9.
3. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med 2005 50 : 426 38.
4. Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005 49 : 253 61.
5. Stewart DJ. Update on the role of topotecan in the treatment of non-small cell lung cancer. Oncologist 2004 9 Suppl. 6 43 52.
6. Honig A, Rieger L, Sutterlin A, Kapp M, Dietl J, Sutterlin MW et al. Brain metastases in breast cancer - an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res 2005 25 : 1531 7.
7. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radio-sensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005 20 : 195 9.
8. Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM et al. A phase I and pharmacodynamic study of fludarabine, carboplatin and topotecan in patients with relapsed, refractory or high-risk acute leukemia. Clin Cancer Res 2004 10 : 6830 9.
9. D'Arpa P, Liu LF. Topoisomerase-targeting anti-tumor drugs. Biochim Biophys Acta 1989 989 : 163 77.
10. Fukasawa K, Komatani H, Hara Y, Suda H, Okura A, Nishimura S et al. Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506. Int J Cancer 1998 75 : 145 50.
11. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL et al. Pharmacokinetics and pharmacodynamics of topotecan in patients' with advanced cancer. Drug Metab Dispos 1992 20 : 706 13.
12. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000 60 : 3389 93.
13. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multi-drug transporter. Annu Rev Genet 1995 29 : 607 49.
14. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (p-glycoprotein) gene from multi-drug-resistant human cells. Cell 1986 47 : 381 9.
15. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992 258 : 1650 4.
16. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005 96 : 457 65.
17. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003 22 : 7340 58.
18. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005 46 : 849 57.
19. Robert J. Approaches to multi-drug resistance reversal. Expert Opin Investig Drugs 1998 7 : 929 39.
20. Arslanagic A, Zulic I, Bajraktarevic A. Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. Med Arh 2005 59 : 346 8.
21. Yoshida J, Ishibashi T, Nishio M. Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells. Eur J Pharmacol 2003 472 : 23 31.
22. Yoshida J, Ishibashi T, Nishio M. Anti-tumour effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo. Eur J Pharmacol 2004 492 : 103 12.
23. Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, Zhang RJ et al. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci 2004 95 : 381 9.
24. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cut-off size. Cancer Res 1995 55 : 3752 6.
25. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG et al. Effective targeting of solid tumours in patients with locally advanced cancers by radio-labelled pegylated liposomes. Clin Cancer Res 2001 7 : 243 54.
26. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 1999 68 : 383 424.
27. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell 1996 85 : 817 27.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983 65 : 55 63.
29. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003 63 : 5126 35.
30. Yuan GP, Chen SZ, Jin NB, Xu SS, Chen B. A reversed phase HPLC method for determination of amlodipine in human plasma. Strait Pharm J (Chinese) 2004 16 : 51 3.
31. Liang ZH, Wu PH, Li L, Xue G, Zeng YX, Huang WL. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein. Chin Med J 2004 117 : 1809 14.
32. Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos 2005 33 : 1220 8.
33. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992 52 : 2413 8.
34. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al. HGS-ETR1, a fully human TRAIL-receptor-1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005 92 : 1430 41.
35. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M et al. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 2005 92 : 681 9.
36. Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J et al. Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 2004 91 : 1067 74.
37. Cattel L, Ceruti M, Dosio F. From conventional to stealthy liposomes: a new frontier in cancer chemotherapy. Tumori 2003 89 : 237 49.
38. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986 22 : 21 5.